[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Palvella Therapeutics Inc (PVLA)

Palvella Therapeutics Inc (PVLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,634,959
  • Shares Outstanding, K 14,343
  • Annual Sales, $ 0 K
  • Annual Income, $ -41,720 K
  • EBIT $ -46 M
  • EBITDA $ -46 M
  • 60-Month Beta -0.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.04

Options Overview Details

View History
  • Implied Volatility 66.91% (+2.10%)
  • Historical Volatility 65.96%
  • IV Percentile 3%
  • IV Rank 3.23%
  • IV High 246.56% on 02/17/26
  • IV Low 60.92% on 05/18/26
  • Expected Move (DTE 23) 14.79 (12.58%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 260
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 3,662
  • Open Int (30-Day) 4,072
  • Expected Range 102.80 to 132.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.16
  • Number of Estimates 4
  • High Estimate $-0.90
  • Low Estimate $-1.42
  • Prior Year $-0.86
  • Growth Rate Est. (year over year) -34.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
101.29 +16.09%
on 05/19/26
132.72 -11.40%
on 04/28/26
-6.00 (-4.85%)
since 04/24/26
3-Month
101.29 +16.09%
on 05/19/26
146.60 -19.79%
on 02/27/26
-30.75 (-20.73%)
since 02/26/26
52-Week
20.20 +482.13%
on 06/18/25
151.18 -22.22%
on 02/26/26
+93.87 (+395.74%)
since 05/23/25

Most Recent Stories

More News
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards

WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing...

PVLA : 117.59 (+3.16%)
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular...

In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Microcystic Lymphatic Malformation Investigator Global...

PVLA : 117.59 (+3.16%)
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) at...

PVLA : 117.59 (+3.16%)
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market

Uplisting reflects Palvella’s continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE)...

PVLA : 117.59 (+3.16%)
Palvella Therapeutics Q1 Earnings Call Highlights

Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting what...

PVLA : 117.59 (+3.16%)
Palvella Therapeutics: Q1 Earnings Snapshot

Palvella Therapeutics: Q1 Earnings Snapshot

PVLA : 117.59 (+3.16%)
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on track...

PVLA : 117.59 (+3.16%)
Palvella's Expected Loss Masks Whether Anyone Actually Wants These Rare Disease Treatments

Barchart Research What to Expect from PVLA Earnings PVLA Generated May 6, 2026 Current Price $130.17 EPS Estimate $$-0.89 Consensus Rating Strong Buy Average Move 3.27% Palvella's Expected Loss Masks Whether...

PVLA : 117.59 (+3.16%)
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S. ...

PVLA : 117.59 (+3.16%)
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing...

PVLA : 117.59 (+3.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

See More

Key Turning Points

3rd Resistance Point 122.35
2nd Resistance Point 119.98
1st Resistance Point 118.78
Last Price 117.59
1st Support Level 115.22
2nd Support Level 112.85
3rd Support Level 111.65

See More

52-Week High 151.18
Last Price 117.59
Fibonacci 61.8% 101.15
Fibonacci 50% 85.69
Fibonacci 38.2% 70.23
52-Week Low 20.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.